<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Standard Biotools Inc — News on 6ix</title>
<link>https://6ix.com/company/standard-biotools-inc</link>
<description>Latest news and press releases for Standard Biotools Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/standard-biotools-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358f1d78dffbe2df1017de.webp</url>
<title>Standard Biotools Inc</title>
<link>https://6ix.com/company/standard-biotools-inc</link>
</image>
<item>
<title>Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-to-announce-first-quarter-2026-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-to-announce-first-quarter-2026-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
<description>BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (NASDAQ: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and</description>
</item>
<item>
<title>Labrador Gold Announces Closing of Change of Business and Acquisition of Units of Northern Shield</title>
<link>https://6ix.com/company/standard-biotools-inc/news/labrador-gold-announces-closing-of-change-of-business-and-acquisition-of-units-of-northern-shield-1</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/labrador-gold-announces-closing-of-change-of-business-and-acquisition-of-units-of-northern-shield-1</guid>
<pubDate>Mon, 09 Mar 2026 14:15:00 GMT</pubDate>
<description>TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce that it has received final approval from the TSX Venture Exchange (the ”TSXV”) to its Change of Business (“COB”) to a hybrid Mining/investment issuer following approval of the COB by its shareholders at the Annual General & Special Meeting of shareholders held on February 24, 2026 (the “Meeting”). Following the Meeting, the Board of Directors elected at the</description>
</item>
<item>
<title>CORRECTION – Labrador Gold Announces Voting Results of the 2026 Annual General and Special Meeting of Shareholders</title>
<link>https://6ix.com/company/standard-biotools-inc/news/correction-labrador-gold-announces-voting-results-of-the-2026-annual-general-and-special-meeting-of-shareholders-2</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/correction-labrador-gold-announces-voting-results-of-the-2026-annual-general-and-special-meeting-of-shareholders-2</guid>
<pubDate>Wed, 25 Feb 2026 14:42:00 GMT</pubDate>
<description>TORONTO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on Tuesday, February 24, 2026, at 11:00 A.M. (Toronto Time) at Gardiner Roberts LLP, Bay Adelaide Centre, East Tower, 22 Adelaide Street West, Suite 3600, Toronto, Ontario, M5H 4E3 (the “Meeting”). A total of 83,756,898 Common Shares of the Corporation (“Common Shares”) representin</description>
</item>
<item>
<title>Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 24 Feb 2026 21:10:00 GMT</pubDate>
<description>BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow</description>
</item>
<item>
<title>Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announce-fourth-quarter-120000318</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announce-fourth-quarter-120000318</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provid</description>
</item>
<item>
<title>Standard BioTools Completes Sale of SomaLogic to Illumina</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-completes-sale-somalogic-140900267</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-completes-sale-somalogic-140900267</guid>
<pubDate>Fri, 30 Jan 2026 14:09:00 GMT</pubDate>
<description>Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it ha</description>
</item>
<item>
<title>Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announces-preliminary-fourth-120000638</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announces-preliminary-fourth-120000638</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 millionBOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from</description>
</item>
<item>
<title>Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry</title>
<link>https://6ix.com/company/standard-biotools-inc/news/molecular-instruments-and-standard-biotools-announce-collaboration-to-bring-amplified-multi-omic-readouts-to-imaging-mass-cytometry</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/molecular-instruments-and-standard-biotools-announce-collaboration-to-bring-amplified-multi-omic-readouts-to-imaging-mass-cytometry</guid>
<pubDate>Wed, 19 Nov 2025 16:30:00 GMT</pubDate>
<description>LOS ANGELES & SAN FRANCISCO, November 19, 2025--MI & Standard BioTools integrate HCR™ Gold with the Hyperion™ Imaging System to enable amplified RNA and protein detection for Imaging Mass Cytometry.</description>
</item>
<item>
<title>Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks</title>
<link>https://6ix.com/company/standard-biotools-inc/news/illuminar-protein-prep-delivers-groundbreaking-precision-in-ngs-proteomics-for-more-than-40-customers-ranging-from-academic-institutions-to-large-national-biobanks</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/illuminar-protein-prep-delivers-groundbreaking-precision-in-ngs-proteomics-for-more-than-40-customers-ranging-from-academic-institutions-to-large-national-biobanks</guid>
<pubDate>Mon, 10 Nov 2025 17:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at the lowest cost per protein target for more than 40 customers across 16 sites globally. Labs of all sizes are creating powerful layers of omic data for a range of diseases that enrich datasets generated by biobank programs around the world.</description>
</item>
<item>
<title>Standard BioTools Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-third-quarter-210500750</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-third-quarter-210500750</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. Recent Highlights: Third quarter 2025 total combined company revenue of $46.2 million; Revenue from continuing operations of $19.6 millionImplemented restructuring plan expected to deliver over $40 million in annualized cost savings; On track to achieve positive adjusted EBITDA target</description>
</item>
<item>
<title>Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announce-third-quarter-110000974</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announce-third-quarter-110000974</guid>
<pubDate>Tue, 21 Oct 2025 11:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides</description>
</item>
<item>
<title>Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development</title>
<link>https://6ix.com/company/standard-biotools-inc/news/illuminar-protein-prep-launches-to-drive-greater-proteomic-insights-for-improved-drug-discovery-and-development</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/illuminar-protein-prep-launches-to-drive-greater-proteomic-insights-for-improved-drug-discovery-and-development</guid>
<pubDate>Wed, 03 Sep 2025 13:15:00 GMT</pubDate>
<description>Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale. Illumina Protein Prep has been available through an early-access program, and is now broadly available to customers worldwide, enabling researchers to add proteomics to large-scale genomics studies and fuel new insights across cancer and cardio metabolic and immunologic diseases, with a streamlined sa</description>
</item>
<item>
<title>Standard BioTools Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-second-quarter-200100764</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-second-quarter-200100764</guid>
<pubDate>Mon, 11 Aug 2025 20:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounc</description>
</item>
<item>
<title>Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-precision-health-research-110000314</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-precision-health-research-110000314</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-</description>
</item>
<item>
<title>Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-schedules-second-quarter-110000454</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-schedules-second-quarter-110000454</guid>
<pubDate>Mon, 21 Jul 2025 11:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio</description>
</item>
<item>
<title>Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy</title>
<link>https://6ix.com/company/standard-biotools-inc/news/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-multiomics-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-multiomics-strategy</guid>
<pubDate>Wed, 25 Jun 2025 04:16:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.</description>
</item>
<item>
<title>Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-enters-next-phase-110500034</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-enters-next-phase-110500034</guid>
<pubDate>Mon, 23 Jun 2025 11:05:00 GMT</pubDate>
<description>Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIR</description>
</item>
<item>
<title>Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-host-inaugural-proteomics-110000485</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-host-inaugural-proteomics-110000485</guid>
<pubDate>Fri, 30 May 2025 11:00:00 GMT</pubDate>
<description>Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical developmentSOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and i</description>
</item>
<item>
<title>Standard BioTools Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-first-quarter-200100595</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-reports-first-quarter-200100595</guid>
<pubDate>Tue, 06 May 2025 20:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 mil</description>
</item>
<item>
<title>Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025</title>
<link>https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announces-product-innovations-110000125</link>
<guid isPermaLink="true">https://6ix.com/company/standard-biotools-inc/news/standard-biotools-announces-product-innovations-110000125</guid>
<pubDate>Thu, 24 Apr 2025 11:00:00 GMT</pubDate>
<description>Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming Ameri</description>
</item>
</channel>
</rss>